British pharmaceutical giant AstraZeneca is interested in buying Gilead, the US drug maker with the potential to treat new crown drugs, Ridsiewe. AstraZeneca and Gilead had initial contact spree last month about a potential acquisition, Bloomberg reported on June 7, citing people familiar with the matter. If the deal is implemented, it would be the largest pharmaceutical deal ever made. News on this to AstraZeneca public relations staff to verify, the other side replied: “I don’t know.” As of this time, Gilead Sciences has not responded to this.
As of the close of EASTERN Time on June 5, Gilead Sciences had a market capitalisation of about $96.273 billion and AstraZeneca had a total market capitalisation of about $141.331 billion.
AstraZeneca’s 2019 earnings report on February 14th reported total revenue of $24.384 billion, up 10 percent from a year earlier. China’s revenue was $4.88 billion, up 35% year-on-year and accounting for 20.7% of AstraZeneca’s global revenue.
According to gilead Science’s February 4 financial results, Gilead Sciences’ fiscal 2019 revenue was $22,449 million, up 1.46 percent from a year earlier, while net income attributable to the parent company’s common shareholders was $5.386 billion, down 1.26 percent from a year earlier.
AstraZeneca, formed by the merger of the former Swedish Astra company and the former British company Jellicon in 1999, is headquartered in the UK and entered China in 1993, with a number of products in the fields of neurology, respiration, digestion, cardiovascular/metabolic, oncology and anesthesia.
Founded in 1987 and headquartered in the United States, Gilead Sciences entered China in 2016 with products covering the fields of AIDS, hepatitis B, hepatitis C, cardiovascular disease, cystic fibrosis, respiratory diseases and antifungals.
It’s worth noting that both AstraZeneca and Gilead Sciences invested in the new corona outbreak.
AstraZeneca has teamed up with Oxford University to develop a vaccine specifically for new coronary pneumonia, and if all goes well, AstraZeneca is expected to provide 30m doses in September. In addition, on April 14, AstraZeneca announced on its official website that it would launch a randomized, global clinical trial to assess the potential of BTK inhibitor Calquence (acalabrutinib) in treating patients with severe immunoremotic response (cytokine storm) with COVID-19 infection.
Gilead Scientific’s anti-new coronary drug, Redsywe, has been approved in Japan as japan’s first new coronary treatment drug, and in the United States has obtained an FDA emergency use authorization to treat seriously ill new coronal patients